Savara Inc. (SVRA)
Nasdaq · Healthcare · Biotechnology
$4.78−0.62%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $982M
- 52-week range
- $3.34 – $7.01
- 52-week change
- +40.23%
- EPS (trailing)
- −$0.58
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$119M
- Diluted EPS
- −$0.53
- Free cash flow
- −$101M
From the company’s annual report on SEC EDGAR.
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Headquarters: Yardley, United States · 70 employees · savarapharma.com